# US 2017/0281744 A1 · Method of treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281744 A1
- Document ID: US20170281744A1
- Status: Published application
- Kind: A1
- Application number: 15/529,094
- Filed: 2015-12-08
- Published: 2017-10-05
- Earliest claimed: 2014-12-10
- Assignees: Glaxosmithkline Biologicals SA
- Applicants: GlaxoSmithKline Biologicals SA
- Inventors: Ralph Leon BIEMANS; Dominique BOUTRIAU; Philippe DENOEL; Pierre DUVIVIER; Carine GORAJ
- Web page: https://patentgrep.com/patent/US20170281744A1

## CPC

- A61K 39/085: Staphylococcus
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 14/31: from Staphylococcus (G)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/555: {characterised by a specific combination antigen/adjuvant}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The application discloses a method of immunising against Staphylococcus aureus infection comprising a step of administering to a human patient a single dose of an immunogenic composition comprising; (i) a Staphylococcus aureus ClfA protein or immunogenic fragment thereof at a dose of 5-50, 10-30, 5-15 or 20-40 μg and (ii) a pharmaceutically acceptable excipient; wherein the pH of the composition is pH 5.0-pH 8.0. The application further discloses an immunogenic composition comprising; (i) a S. aureus Type 5 capsular saccharide conjugated to a carrier protein, (ii) a S. aureus Type 8 capsular saccharide conjugated to a carrier protein, (iii) a ClfA protein or immunogenic fragment thereof, (iv) an alpha toxoid, and (v) a pharmaceutically acceptable excipient; wherein the pH of the immunogenic composition is pH 5.0-pH 8.0

## Claims

### Claim 1

A method of treating or preventing a Staphylococcus aureus infection in a human patient, comprising administering to the patient a single dose of an immunogenic composition comprising; (i) a Staphylococcus aureus ClfA protein or immunogenic fragment thereof at a dose of 5-50, 10-30, 5-15 or 20-40 μg, and (ii) a pharmaceutically acceptable excipient; wherein the pH of the immunogenic composition is pH 5.0-8.0.

### Claim 2 (depends on 1)

The method of claim 1 wherein the ClfA protein or immunogenic fragment thereof is at least 90% identical to the polypeptide sequence of any one of SEQ ID NO:3-12 or 15-18 along the full length thereof.

### Claim 3 (depends on 1)

The method of claim 1 wherein the ClfA protein or immunogenic fragment thereof is a fragment of ClfA comprising a N2 domain.

### Claim 4 (depends on 1)

The method of claim 1 wherein the ClfA protein or immunogenic fragment thereof is a fragment of ClfA comprising a N3 domain.

### Claim 5 (depends on 1)

The method of claim 1 wherein the ClfA protein or immunogenic fragment thereof is a fragment of ClfA comprising a N1 domain.

### Claim 6 (depends on 1)

The method of claim 1 wherein the ClfA protein or immunogenic fragment thereof contains an amino acid substitution which reduces the ability of ClfA to bind to fibrinogen.

### Claim 7 (depends on 6)

The method of claim 6 wherein the ClfA protein or immunogenic fragment thereof contains an amino acid substitution at at least one of amino acids Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Tyr474, Glu526 or Val527.

### Claim 8 (depends on 1)

The method of claim 1 wherein the ClfA protein or immunogenic fragment thereof is present in the immunogenic composition at a dose of 20-40 μg.

### Claim 9 (depends on 1)

The method of claim 1 wherein the immunogenic composition comprises an alpha toxoid protein.

### Claim 10 (depends on 9)

The method of claim 9 wherein the alpha toxoid protein has an amino acid sequence at least 90% identical to SEQ ID NO:1, 2, 13 or 14.

### Claim 11 (depends on 9)

The method of claim 9 wherein the alpha toxoid protein is present in the immunogenic composition at a dose of 5-50, 10-30, 5-15 or 20-40 μg.

### Claim 12 (depends on 1)

The method of claim 1 wherein the single dose of the immunogenic composition is administered 5-60, 6-40, 7-30 or 7-15 days before a planned hospital procedure.

### Claim 13

A method of treating or preventing a Staphylococcus aureus infection in a human patient, comprising administering to the patient a single dose of an immunogenic composition comprising; (i) a Staphylococcus aureus alpha toxoid protein or immunogenic fragment thereof at a dose of 5-50, 10-30, 5-15 or 20-40 μg, and (ii) a pharmaceutically acceptable excipient; wherein the pH of the immunogenic composition is pH 5.0-pH 8.0.

### Claim 14 (depends on 13)

The method of claim 13, wherein the alpha toxoid protein or immunogenic fragment thereof has an amino acid sequence at least 90% identical to SEQ ID NO:1, 2, 13 or 14.

### Claim 15

An immunogenic composition comprising; (i) a S. aureus Type 5 capsular saccharide conjugated to a carrier protein, (ii) a S. aureus Type 8 capsular saccharide conjugated to a carrier protein, (iii) a ClfA protein or immunogenic fragment thereof, (iv) an alpha toxoid, and (v) a pharmaceutically acceptable excipient; wherein the pH of the immunogenic composition is pH 5.0-pH 8.0.

### Claim 16 (depends on 15)

A process for making the immunogenic composition of claim 15 comprising the steps of a) conjugating a S. aureus Type 5 capsular saccharide to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate, b) conjugating a S. aureus Type 8 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 8 capsular saccharide conjugate, and c) combining the S. aureus Type 5 capsular saccharide conjugate, the S. aureus Type 8 capsular saccharide conjugate, a ClfA protein or immunogenic fragment thereof and an alpha toxoid to form the immunogenic composition.

### Claim 17 (depends on 13)

The method of claim 13, wherein the single dose of the immunogenic composition is administered 5-60, 6-40, 7-30 or 7-15 days before a planned hospital procedure.

### Claim 18 (depends on 9)

The method of claim 9, wherein the single dose of the immunogenic composition further comprises a S. aureus Type 5 capsular saccharide conjugated to a carrier protein and a S. aureus Type 8 capsular saccharide conjugated to a carrier protein.
